These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 14760366)

  • 1. Control of oncogenesis and cancer therapy resistance.
    Perona R; Sánchez-Pérez I
    Br J Cancer; 2004 Feb; 90(3):573-7. PubMed ID: 14760366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signalling pathways involved in clinical responses to chemotherapy.
    Perona R; Sánchez-Pérez I
    Clin Transl Oncol; 2007 Oct; 9(10):625-33. PubMed ID: 17974523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment.
    Rodriguez-Nieto S; Zhivotovsky B
    Curr Pharm Des; 2006; 12(34):4411-25. PubMed ID: 17168751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.
    Krakstad C; Chekenya M
    Mol Cancer; 2010 Jun; 9():135. PubMed ID: 20515495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis, cancer and cancer therapy.
    Bold RJ; Termuhlen PM; McConkey DJ
    Surg Oncol; 1997 Nov; 6(3):133-42. PubMed ID: 9576629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis in cancer--implications for therapy.
    Schulze-Bergkamen H; Krammer PH
    Semin Oncol; 2004 Feb; 31(1):90-119. PubMed ID: 14970941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.
    Wendel HG; De Stanchina E; Fridman JS; Malina A; Ray S; Kogan S; Cordon-Cardo C; Pelletier J; Lowe SW
    Nature; 2004 Mar; 428(6980):332-7. PubMed ID: 15029198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Apoptosis resistance in malignant tumors: novel apoptosis-based therapeutic approaches].
    Roth W
    Pathologe; 2009 Dec; 30 Suppl 2():113-6. PubMed ID: 19756623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
    Sims JT; Ganguly SS; Bennett H; Friend JW; Tepe J; Plattner R
    PLoS One; 2013; 8(1):e55509. PubMed ID: 23383209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-apoptotic mechanisms of drug resistance in cancer.
    Wilson TR; Johnston PG; Longley DB
    Curr Cancer Drug Targets; 2009 May; 9(3):307-19. PubMed ID: 19442051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.
    Hua H; Kong Q; Yin J; Zhang J; Jiang Y
    J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the mysteries of IGF-1 signaling in melanoma.
    Lee JT; Brafford P; Herlyn M
    J Invest Dermatol; 2008 Jun; 128(6):1358-60. PubMed ID: 18478012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.
    Singh PP; Joshi S; Russell PJ; Nair S; Khatri A
    BMC Cancer; 2011 Aug; 11():368. PubMed ID: 21861932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptotic pathways and therapy resistance in human malignancies.
    Viktorsson K; Lewensohn R; Zhivotovsky B
    Adv Cancer Res; 2005; 94():143-96. PubMed ID: 16096001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro-oxidant milieu blunts scissors: insight into tumor progression, drug resistance, and novel druggable targets.
    Pervaiz S
    Curr Pharm Des; 2006; 12(34):4469-77. PubMed ID: 17168754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms for tumour resistance to chemotherapy.
    Pan ST; Li ZL; He ZX; Qiu JX; Zhou SF
    Clin Exp Pharmacol Physiol; 2016 Aug; 43(8):723-37. PubMed ID: 27097837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted manipulation of apoptosis in cancer treatment.
    Call JA; Eckhardt SG; Camidge DR
    Lancet Oncol; 2008 Oct; 9(10):1002-11. PubMed ID: 18760670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting apoptosis in cancer therapy.
    Carneiro BA; El-Deiry WS
    Nat Rev Clin Oncol; 2020 Jul; 17(7):395-417. PubMed ID: 32203277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.